Protagonist Stock Upgraded by Goldman Sachs on Autoimmune Asset Potential

Protagonist Therapeutics received an upgrade from Goldman Sachs, citing the potential of its autoimmune asset. This financial news highlights investor confidence in the company's pharmaceutical developments.